«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:

21卷

期数:

2015年01期

页码:

51-54

栏目:

临床医学

出版日期:

2015-01-20

文章信息/Info

Title:

Clinical observation of icotinib hydrochloride in the treatment of advanced non-small cell lung cancer

文章编号:

1006-8147（2015）0-0051-04

作者:

梁绍平; 王华庆

(天津医科大学肿瘤医院淋巴瘤科,国家肿瘤临床医学研究中心,天津市肿瘤防治重点实验室,天津300060)

Author(s):

LIANG Shao-ping WANG Hua-qing

(Department of Lymphoma, Cancer Institute and Hospital， Tianjin Medical University, National Clinical Research Center of Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060,China)

关键词:

盐酸埃克替尼; 非小细胞肺癌; 表皮生长因子受体; 分子靶向治疗

Keywords:

icotinib hydrochloride;  advanced non-small cell lung cancer;  epidermal growth factor receptor ; molecular target therapy

分类号:

R734.2

DOI:

-

文献标志码:

A

摘要:

目的：观察盐酸埃克替尼治疗晚期非小细胞肺癌的临床疗效及安全性。方法：回顾分析埃克替尼治疗30例晚期非小细胞肺癌的临床效果，采用口服治疗，125 mg/次，3次/d，评价其近期疗效、无病进展生存期及不良反应。结果:30例患者在接受埃克替尼1个月治疗后，完全缓解（CR）0例，部分缓解（PR）10例，疾病稳定（SD）14例，疾病进展（PD）6例，客观有效率（ORR）为33.3%，疾病控制率（DCR）为80%。在各临床因素中，ECOG评分及是否伴有脑转移与近期疗效具有相关性（P<0.05）。截至随访结束，24例（80%）出现PFS终点事件，全组中位PFS为8.0个月。患者的PFS主要与患者年龄、吸烟与否、ECOG评分以及是否伴有其他部位的转移有关（P<0.05）。全组不良反应发生率为43.3%，主要为皮疹5例（16.7%），皮肤瘙痒2例（6.7%），腹泻 1例(3.3% )，胃部不适1例( 3.3%)，肝功能轻度损害6例(20.0% )。结论：盐酸埃克替尼治疗晚期非小细胞肺癌疗效肯定，耐受性好。

Abstract:

Objective ： To observe the clinical effect and toxicity of icotinib in 30 patients with advanced NSCLC. Methods: Thirty patients with advanced NSCLC were retrospectively analyzed. Icotinib (125 mg,three times a day) was orally taken by patients, to evaluate the short-term response, progression free survival and toxicity. Results： Among the 30 patients, no cases experienced complete response(CR), 10 cases experienced partial response(PR), 14 cases were with stable diseases(SD), 6 cases were with progression disease(PD), and the tumor objective response rate (ORR) and disease control rate(DCR) were 33.3%(10/30) and 80.0%(24/30), respectively. ECOG and brain metastasis were associated with short-term response. At the end of the follow-up period, twenty-four cases had progression disease. The median PFS was 8.0 months, significantly correlated with age, smoking history, ECOG, and metastasis (P<0.05). The incidence of side effects was 43.3%, including rash (16.7%) ,itch of skin(6.7%) ,diarrhea(3.3%) , heartburn(3.3%), and mild impair of liver function(20.0%). Conclusion: Icotinib hydrochloride is effective with high drug tolerance for advanced non-small cell lung cancer.

参考文献/References:

[1]Kumar A, Petri E T, Halmos B, et al. Structure and clinical relevance of the epidermal growth factor receptor in human Cancer[J]. J Clin Oncol, 2008,26(10):1742
[2]Mok T S, Wu Y L, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma[J]. N Engl J Med, 2009,361(10):947
[3]Pérez-Soler R, Chachoua A, Hammond L A, et al. Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung Cancer[J]. J Clin Oncol, 2004,22(16):3238
[4]谭芬来，张力，赵琼，等. 国家一类新药盐酸埃克替尼的药理与临床评价[J]. 中国新药杂志, 2009, (18):1691
[5]Shi Y, Zhang L, Liu X, et al. Icotinib versus gefitinib in previously treated advanced non-small-cell lung Cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial[J]. Lancet Oncol, 2013,14(10):953
[6]Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung Cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial[J]. Lancet Oncol, 2010,11(2):121
[7]Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung Cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial[J]. Lancet Oncol, 2012,13(3):239
[8]Zhou C, Wu Y L, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung Cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study[J]. Lancet Oncol, 2011,12(8):735
[9]王雷，刘基巍，于佩瑶. 盐酸埃克替尼治疗66例晚期非小细胞肺癌的临床研究[J]. 中国新药杂志, 2013, (16):1930
[10]Janne P A, Wang X, Socinski M A, et al. Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial[J]. J Clin Oncol, 2012,30(17):2063
[11]Wu Y L, Lee J S, Thongprasert S, et al. Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung Cancer (FASTACT-2): a randomised, double-blind trial[J]. Lancet Oncol, 2013,14(8):777
[12]Goldberg S B, Oxnard G R, Digumarthy S, et al. Chemotherapy with Erlotinib or chemotherapy alone in advanced non-small cell lung Cancer with acquired resistance to EGFR tyrosine kinase inhibitors[J]. Oncologist, 2013,18(11):1214
[13]Weber B, Winterdahl M, Memon A, et al. Erlotinib accumulation in brain metastases from non-small cell lung Cancer: visualization by positron emission tomography in a patient harboring a mutation in the epidermal growth factor receptor[J]. J Thorac Oncol, 2011,6(7):1287
[14]Ma S, Xu Y, Deng Q, et al. Treatment of brain metastasis from non-small cell lung Cancer with whole brain radiotherapy and Gefitinib in a Chinese population[J]. Lung Cancer, 2009,65(2):198
[15]Heon S, Yeap B Y, Lindeman N I, et al. The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung Cancer with EGFR mutations[J]. Clin Cancer Res, 2012,18(16):4406

相似文献/References:

[1]李晶鑫,许芳秀,王玉,等.NFAT2在非小细胞肺癌中的表达及预后关联研究[J].天津医科大学学报,2016,22(05):417.
　LI Jing-xin,XU Fang-xiu,WANG Yu,et al.Relationship between expression of NFAT2 and survival prognosis in? non-small cell lung cancer[J].Journal of Tianjin Medical University,2016,22(01):417.
[2]李晶鑫,许芳秀,王玉,等.NFAT2在非小细胞肺癌中的表达及预后关联研究[J].天津医科大学学报,2016,22(05):417.
　LI Jing-xin,XU Fang-xiu,WANG Yu,et al.Relationship between expression of NFAT2 and survival prognosis in? non-small cell lung cancer[J].Journal of Tianjin Medical University,2016,22(01):417.
[3]黄晓莹.MRI与CT在非小细胞肺癌淋巴结转移诊断中的应用价值比较[J].天津医科大学学报,2017,23(06):542.
　HUANG Xiao-ying.Application value of MRI and CT in the diagnosis of lymph node metastasis of non-small cell lung cancer[J].Journal of Tianjin Medical University,2017,23(01):542.
[4]高会霞,王 彬,方 黎,等.3DCRT联合化疗对晚期NSCLC患者近期疗效及血清肿瘤标记物的影响[J].天津医科大学学报,2019,25(05):507.
[5]王红军,贾金广,朱婉凌,等.CXCL-14在非小细胞肺癌中的表达水平及临床意义[J].天津医科大学学报,2021,27(02):112.
　WANG Hong-jun,JIA Jin-guang,ZHU Wan-ling,et al.The expression level and clinical significance of CXCL-14 in non-small cell lung cancer[J].Journal of Tianjin Medical University,2021,27(01):112.
[6]张萌,孟昭婷,张翠翠,等.Super-ARMS法检测EGFR突变在NSCLC的临床应用[J].天津医科大学学报,2021,27(02):185.
　ZHANG Meng,MENG Zhao-ting,ZHANG Cui-cui,et al.Clinical application of EGFR mutation in NSCLC detect by the way of Super-arms[J].Journal of Tianjin Medical University,2021,27(01):185.
[7]严一杰,张军,王硕,等.125I粒子植入的靶区勾画对一线治疗后局部进展的非小细胞肺癌治疗效果影响[J].天津医科大学学报,2021,27(06):586.
　YAN Yi-jie,ZHANG Jun,WANG Shuo,et al.Effect of target delineation of 125I seed implantation on the treatment of locally advanced non-small cell lung cancer after first-line therapy[J].Journal of Tianjin Medical University,2021,27(01):586.
[8]陈嫱,英硕,李冠华,等.非小细胞肺癌M1期患者的危险、预后因素和转移特征：一项基于SEER数据库的研究[J].天津医科大学学报,2022,28(01):27.
　CHEN Qiang,YING Shuo,LI Guan-hua,et al.The risk，prognostic factors and metastatic features for patients with M1 stage of non-small cell lung cancer: a SEER-based study[J].Journal of Tianjin Medical University,2022,28(01):27.
[9]张静怡,迟航,杨鑫,等.Ras相关区域家族10蛋白在非小细胞肺癌中的表达及预后价值[J].天津医科大学学报,2024,30(05):385.[doi:10.20135/j.issn.1006-8147.2024.05.0385]
　ZHANG Jingyi,CHI Hang,YANG Xin,et al.The expression and prognostic value of ras-association domain family 10 in non-small cell lung cancer[J].Journal of Tianjin Medical University,2024,30(01):385.[doi:10.20135/j.issn.1006-8147.2024.05.0385]
[10]梁绍平,王华庆.盐酸埃克替尼治疗晚期非小细胞肺癌的临床疗效观察[J].天津医科大学学报,2015,21(03):51.
　LIANG Shao-ping,WANG Hua-qing.Clinical observation of icotinib hydrochloride in the treatment of advanced non-small cell lung cancer[J].Journal of Tianjin Medical University,2015,21(01):51.

备注/Memo

备注/Memo:

作者简介 梁绍平（1988-），女，硕士在读，研究方向：肿瘤学;通信作者：王华庆，E-mail：huaqingw@163 .com。

常用功能

更新日期/Last Update: 2015-06-10